Investors / Media
View our Corporate PresentationRecent News & Articles
NRx Pharmaceuticals Provides Progress Update on Interactions with the FDA regarding Path to NDA Submission for NRX-101
NRx Pharmaceuticals, Inc. today announced that it had a meeting and a written response from the Food and Drug Administration (FDA) last week regarding its lead compound, NRX-101.
NRx Pharmaceuticals to Present Scientific Update at the 6th Annual Sachs Associates Neuroscience Innovation Forum in Conjunction with the 2023 J.P. Morgan Healthcare Conference
NRx Pharmaceuticals, Inc. today announced that it will be presenting a scientific update of its Phase 2 and Phase 3 development program for NRX-101 in the treatment of suicidal bipolar depression at the upcoming 6th Annual Neuroscience Innovation Forum by Sachs Associates.
NRx Pharmaceuticals Initiates Phase 3 Trial Treating Patients with Bipolar Depression with Acute Suicidality – First Clinical Site Contracted
NRx Pharmaceuticals, Inc. today announced it has initiated a Phase 3 registrational trial targeting suicidal bipolar depression with suicidality and has signed the first clinical site contract.
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. today announced the close of the definitive settlement agreements to resolve the pending litigation between Relief and NRx Pharmaceuticals’ wholly owned subsidiary, NeuroRx, Inc.
NRx Pharmaceuticals Announces the Appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP, Senior Vice President of Clinical Development and Medical Affairs
NRx Pharmaceuticals today announced the appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP as Senior Vice President, Clinical Development and Medical Affairs. She will lead the Company’s clinical development program and provide medical oversight across all indications. Dr. Carretta will report to the Chief Executive Officer and Director.
NRx Receives Nasdaq Notice of Listing Compliance
NRx Pharmaceuticals today announced it received written notice on December 1, 2022 from The Nasdaq Stock Market informing NRx Pharmaceuticals that it has regained compliance with the minimum bid price requirement under the Nasdaq Listing Rule 5450(a)(1) (which requires the Company to maintain a minimum closing bid price of $1.00 per share) and the matter is now closed.
Investor Relations
Tags
NRx Press Archives
Analyst Coverage
Ascendiant Capital Markets LLC – Member FINRA & SIPC
Edward Woo, CFA
Senior Research Analyst, D.O.R.
H.C. Wainwright & Co., LLC
Vernon Bernadino
Managing Director
Events
To Be Announced
Past Events
41st Annual J.P. Morgan Health Care Conference
January 9-12, 2023
Westin St. Francis Hotel
San Francisco, CA
6th Annual Sachs Associates Neuroscience Innovation Forum
Click here for Video Presentation
January 8, 2023
Ritz Carlton Hotel
San Francisco, CA
Cantor Neurology & Psychiatry Conference
October 6-7, 2022
Ritz Carlton Hotel
San Francisco, CA
HC Wainwright 24th Annual Global Investment Conference
September 12-14, 2022
Lotte New York Palace Hotel
New York, NY
